Hostname: page-component-78c5997874-m6dg7 Total loading time: 0 Render date: 2024-11-14T23:01:30.934Z Has data issue: false hasContentIssue false
  • English
  • Français

Promotion Versus Precaution: The Evolution of Biotechnology Policy in the United States

Published online by Cambridge University Press:  09 March 2006

ADAM D. SHEINGATE
ADAM D. SHEINGATE
Affiliation:
Department of Political Science, Johns Hopkins University.
Get access Rights & Permissions [Opens in a new window]

Abstract

Biotechnology policy in the United States promotes the commercial development of genetically modified crops, yet adopts a precautionary approach when it comes to stem cells and cloning. In this article, the evolution of this bifurcated policy domain is traced. A detailed analysis of congressional hearings shows how distinctions between the products of biotechnology came to be reflected in the character of committees holding hearings, the attention to risks and benefits, and the pattern of interest-group activity in different biotechnology applications. It is argued that many of the differences that separate the United States and Europe in biotechnology reflect the way institutions reinforce past policy choices.

Type
Research Article
Information
British Journal of Political Science , Volume 36 , Issue 2 , April 2006 , pp. 243 - 268
Copyright
2006 Cambridge University Press

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)